# SANTA CRUZ BIOTECHNOLOGY, INC.

# PI 3-kinase p85α (2B2.79): sc-71891



## BACKGROUND

Phosphatidylinositol 3-kinase (PI 3-kinase) is composed of p85 and p110 subunits. p85 lacks PI 3-kinase activity and acts as an adapter, coupling p110 to activated protein tyrosine kinase. Two forms of p85 have been described (p85 $\alpha$  and p85 $\beta$ ), each possessing one SH3 and two SH2 domains. Various p110 isoforms have been identified. p110 $\alpha$  and p110 $\beta$  interact with p85 $\alpha$ , and p110 $\alpha$  has also been shown to interact with p85 $\beta$  *in vitro*. p110 $\delta$  expression is restricted to white blood cells. It has been shown to bind p85 $\alpha$  and  $\beta$ , but it apparently does not phosphorylate these subunits. p110 $\delta$  seems to have the capacity to autophosphorylate. p110 $\gamma$  does not interact with the p85 subunits. It has been shown to be activated by  $\alpha$  and  $\beta\gamma$  heterotrimeric G proteins.

## CHROMOSOMAL LOCATION

Genetic locus: PIK3R1 (human) mapping to 5q13.1; Pik3r1 (mouse) mapping to 13 D1.

### SOURCE

PI 3-kinase p85 $\alpha$  (2B2.79) is a mouse monoclonal antibody raised against recombinant PI 3-kinase p85 $\alpha$  of bovine origin.

### PRODUCT

Each vial contains 1 ml culture supernatant containing  $\text{IgG}_1$  with < 0.1% sodium azide.

## **APPLICATIONS**

PI 3-kinase p85 $\alpha$  (2B2.79) is recommended for detection of the SH3 domain of PI 3-kinase p85 $\alpha$  of mouse, rat and human origin by Western Blotting (starting dilution to be determined by researcher, dilution range 1:10-1:200) and immunoprecipitation [10-20 µl per 100-500 µg of total protein (1 ml of cell lysate)]; non cross-reactive with the p85 $\beta$  isoform.

PI 3-kinase p85 $\alpha$  (2B2.79) is also recommended for detection of the SH3 domain of PI 3-kinase p85 $\alpha$  in additional species, including bovine.

Suitable for use as control antibody for PI 3-kinase p85 $\alpha$  siRNA (h): sc-36217, PI 3-kinase p85 $\alpha$  siRNA (m): sc-36218, PI 3-kinase p85 $\alpha$  siRNA (r): sc-156021, PI 3-kinase p85 $\alpha$  shRNA Plasmid (h): sc-36217-SH, PI 3-kinase p85 $\alpha$  shRNA Plasmid (m): sc-36218-SH, PI 3-kinase p85 $\alpha$  shRNA Plasmid (r): sc-156021-SH, PI 3-kinase p85 $\alpha$  shRNA (h) Lentiviral Particles: sc-36217-V, PI 3-kinase p85 $\alpha$  shRNA (m) Lentiviral Particles: sc-36218-V and PI 3-kinase p85 $\alpha$  shRNA (r) Lentiviral Particles: sc-156021-V.

Molecular Weight of PI 3-kinase p85 $\alpha$ : 85 kDa.

Positive Controls: Pl 3-kinase p85 $\alpha$  (m): 293T Lysate: sc-122557, Caki-1 cell lysate: sc-2224 or COLO 320DM cell lysate: sc-2226.


#### STORAGE


For immediate and continuous use, store at 4° C for up to one month. For sporadic use, freeze in working aliquots in order to avoid repeated freeze/ thaw cycles. If turbidity is evident upon prolonged storage, clarify solution by centrifugation.

## **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### DATA





PI 3-kinase p85 $\alpha$  (2B2.79): sc-71891. Western blot analysis of PI 3-kinase p85 $\alpha$  expression in U-937 (**A**), Caki-1 (**B**), COLO 320DM (**C**), SW480 (**D**) and NIH/3T3 (**E**) whole cell lysates. PI 3-kinase p85 $\alpha$  (282.79): sc-71891. Western blot analysis of PI 3-kinase p85 $\alpha$  expression in non-transfected: sc-117752 (A) and mouse PI 3-kinase p85 $\alpha$  transfected: sc-122557 (B) 293T whole cell lysates.

#### SELECT PRODUCT CITATIONS

- Chen, C.C., et al. 2016. Cannabinoid receptor type 1 mediates high-fat diet-induced Insulin resistance by increasing forkhead box 01 activity in a mouse model of obesity. Int. J. Mol. Med. 37: 743-754.
- Wang, K., et al. 2017. The role of angiopoietin-2 in nucleus pulposus cells during human intervertebral disc degeneration. Lab. Invest. 97: 971-982.
- Xu, M., et al. 2018. SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP-22. Oncol. Rep. 40: 726-736.
- Peng, C.C., et al. 2019. Renal damaging effect elicited by bicalutamide therapy uncovered multiple action mechanisms as evidenced by the cell model. Sci. Rep. 9: 3392.
- 5. Johnson, J., et al. 2020. Targeting PI3K and AMPK $\alpha$  signaling alone or in combination to enhance radiosensitivity of triple negative breast cancer. Cells 9: E1253.

#### PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.